STAT5A and breast cancer: Pimozide, an FDA-approved psychotropic drug, inactivated STAT5a and downregulated the expression of ABCB1, thus sensitizing MCF7/DOX cells to DOX in vitro and in vivo, providing a promising strategy for treating patients with chemoresistant breast cancer in the clinic.